Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Inclusion Criteria: Diagnosis of SSc based on ACR/ EULAR criteria (2013) Overall duration of SSc < 48 months from the first non-Raynaud symptom manifestation HRCT obtained at the Screening Visit or within the 3 months prior to Screening consistent with SSc-ILD (adjudicated by a central reader) AND with pulmonary involvement > 10% Clinical presentation at Screening consistent with lcSSc (up to 40% of patients) or dcSSc Presence of at least: Any 1 laboratory marker for active disease OR Clinically significant decline in FVC % predicted (%pred) based on ≥ 105% relative decline over the preceding one year (two readings from the same pulmonary function laboratory) MMF of ≥ 2 gm/day (or equivalent doses of other mycophenolate based compounds) for 6 months Exclusion Criteria: Pulmonary disease with FVC %pred ≤ 45% OR DLco %pred ≤ 30%; FEV1/FVC ratio < 0.7 Participants with pulmonary artery hypertension on parenteral therapy or with clinical evidence of right heart failure HRCT obtained in the 3 months prior to Screening consistent with other confounding pathology. Treatment with corticosteroids (> 10 mg/day of prednisone or equivalent) within 2 weeks prior to baseline SSc-ILD treatments other than MMF OR MMF < 2 gm/day Any previous treatment with any of the following: rituximab, intravenous immune globulin (IVIG), nintedanib, tocilizumab, cyclophosphamide, pirfenidone, tyrosine-kinase inhibitors (e.g., imatinib, nilotinib, dasatinib) Rheumatic autoimmune disease other than SSc, Is an active, heavy smoker of tobacco/nicotine-containing products History of (anti-Jo-1) anti-synthetase syndrome or Jo-1 positive at Screening